Initial platelet serotonin (5-HT) transport kinetics predict nortriptyline treatment outcome

Journal of Clinical Psychopharmacology

Volumn 23, Issue 2, 2003, Pages 138-144

  Rausch, Jeffrey L ^a   Moeller, Frederick G ^b   Johnson, Maria E ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; FLUVOXAMINE; NORTRIPTYLINE; SEROTONIN; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; CELL LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE; TREATMENT OUTCOME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; BLOOD PLATELETS; CARRIER PROTEINS; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; KINETICS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; NORTRIPTYLINE; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TREATMENT OUTCOME;

EID: 0037381717     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200304000-00006     Document Type: Article

References (50)

1. Joyce PR, Paykel ES. Predictors of drug response in depression. Arch Gen Psychiatry 1989;46:89-99.
2. Rausch JL. An hypothesis of initial conditions: receptor-effector systems as determinants of psychopharmacologic drug response. Int J Neuropsychopharm 1998;1:137-51.
3. Richelson E. Antidepressants and brain neurochemistry. Mayo Clin Proc 1990;65:1227-36.
4. Price LH, Charney DS, Delgado PL, et al. Clinical data on the role of serotonin in the mechanism(s) of action of antidepressant drugs. J Clin Psychiatry 1990;51(April Suppl):44-50; discussion.
5. Cowen PJ. A role for 5-HT in the action of antidepressant drugs. Pharmacol Ther 1990;46:43-51.
6. Blier P, de Montigny C, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry 1990;51(April Suppl):14-20.
7. Shopsin B, Friedman E, Gershon S. Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 1976;33:811-9.
8. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990;47:411-8.
9. Montgomery SA. The benefits and risks of 5-HT uptake inhibitors in depression. Br J Psychiatry 1988;3(suppl):7-10.
10. Asberg M, Eriksson B, Martensson B, et al. Therapeutic effects of serotonin uptake inhibitors in depression. J Clin Psychiatry 1986;47 (April Suppl):23-35.
11. Muijen M, Roy D, Silverstone T, et al. A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatr Scand 1988;78:384-90.
12. Da Prada M, Picotti GB. Content and subcellular localization of catecholamines and 5-hydroxytryptamine in human and animal blood platelets: monoamine distribution between platelets and plasma. Br J Pharmacol 1979;65:653-62.
13. Lingjaerde O. Blood platelets as a model system for studying the biochemistry of depression. In: Usdin E, Asberg M, Bertilsson L, et al, eds. Biological and pharmacological research in depression: advances in biochemical psychopharmacology. 39th ed. New York: Raven Press, 1984:99-111.
14. Pletscher A, Affolter H, Cesura AM, et al. Blood platelet as a model for neurons: similarities for the 5-hydroxytrypmmine systems. In: Schlossenberger HG, Kochen W, Linzen B, et al, eds. Progress in tryptophan and serotonin research. Berlin and New York: Walter de Gruyter & Co., 1984:231-9.
15. Wirz-Justice A. Platelet research in psychiatry. Experientia 1988;44: 145-52.
16. Kannengeiser MH, Hunt P, Raynaud JP. An in vitro model for the study of psychotropic drugs as a criterion of antidepressant activity. Biochem Pharmacol 1973;22:73-84.
17. Ross SB, Aperia B, Beck-Friis J, et al. Inhibition of 5-hydroxytryptamine uptake in human platelets by antidepressant agents in vivo. Psychopharmacology 1980;67:1-7.
18. Maitre L, Moser P, Baumann PA, et al. Amine uptake inhibitors: criteria of selectivity. Acta Psychiatr Scand 1980;280(suppl):97-110.
19. Da Prada M, Cesura AM, Launay JM, et al. Platelets as a model for neurons? Experientia 1988;44:115-26.
20. Asberg M, Cronholm B, Sjoqvist F, et al. Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J 1971;3:331-4.
21. Burrows GD, Davies B, Scoggins BA. Plasma concentration of nortriptyline and clinical response in depressive illness. Lancet 1972;2: 619-23.
22. Ziegler VE, Clayton PJ, Biggs JT. A comparison study of amitriptyline and nortriptyline with plasma levels. Arch Gen Psychiatry 1977;34:607-12.
23. Hollister LE. Monitoring tricyclic antidepressant plasma concentrations. JAMA 1979;241:2530-3.
24. Hanin I, Koslow SH, Kocsis JH, et al. Cerebrospinal fluid levels of amitriptyline, nortriptyline, imipramine and desmethylimipramine. Relationship to plasma levels and treatment outcome. J Affective Disord 1985;9:69-78.
25. Meltzer HY, Arora RC, Baber R, et al. Serotonin uptake in blood platelets of psychiatric patients. Arch Gen Psychiatry 1981;38:1322-6.
26. Rausch JL, Hutcheson J, Li J. Correlations of drug action between human platelet and human brain 5-HTT. Biol Psychiatry 1995;37:600.
27. Barker EL, Blakely RD. Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol Pharmacol 1996;50:957-65.
28. Rausch JL, Hobby HM, Shendarkar N, et al. Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis. J Clin Psychopharmacol 2001;21:139-42.
29. Rausch JL, Johnson ME, Fei Y, et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 2002;51:723-32.
30. Cleland WW. The statistical analysis of enzyme kinetic data. Adv Enzymol 1967;29:1-32.
31. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989;262:914-9.
32. Bielski BJ, Friedel RO. Prediction of tricyclic antidepressant response. Am J Psychiatry 1976;33:1479-89.
33. Stern SL, Rush AJ, Mendels J. Toward a rational pharmacotherapy of depression. Am J Psychiatry 1980;137:545-52.
34. Balon R. Biological predictors of antidepressant treatment outcome. Clin Neuropharmacol 1989;12:195-214.
35. Tuomisto J, Tukiainen E, Ahlfors UG. Decreased uptake of 5-hydroxytryptamine in blood platelets from patients with endogenous depression. Psychopharmacology 1979;65:141-7.
36. Rausch JL, Janowsky DS, Risch SC, et al. A kinetic analysis and replication of decreased platelet serotonin uptake in depressed patients. Psychiatry Res 1986;19:105-12.
37. Åberg-Wistedt A, Jostell K-G, Ross SB, et al. Effects of zimelidine and desipramine on serotonin and noradrenaline uptake mechanisms in relation to plasma concentrations and to therapeutic effects during treatment of depression. Psychopharmacology 1981;74:297-305.
38. Lingjaerde O, Bratfos O, Bratlid T, et al. A double-blind comparison of zimelidine and desipramine in endogenous depression. Acta Psychiatr Scand 1983;68:22-30.
39. Coppen A, Rama Rao VA, Swade C, et al. Inhibition of 5-hydroxytryptamine reuptake by amitriptyline and zimelidine and its relationship to their therapeutic action. Psychopharmacology 1979;63:125-9.
40. Arora RC, Meltzer HY. Effects of amoxapine on serotonin uptake in human blood platelets of depressed patients and normal controls. Psychiatry Res 1983;9:29-36.
41. Figueras G, Perez V, San Martino O, et al. Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Grupo de Trastornos Afectivos. Biol Psychiatry 1999;46:518-24.
42. Celada P, Dolera M, Alvarez E, et al. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients: relationship to clinical improvement. J Affect Disord 1992;25:243-9.
43. Smeraldi E, Zanardi R, Benedetti F, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998;3:508-11.
44. Benedetti F, Serretti A, Colombo C, et al. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. Am J Psychiatry 1999;156:1450-2.
45. Pollock BG, Ferrel RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23:587-90.
46. Blakely RD, De Felice LJ, Hartzell HC. Molecular physiology of norepinephrine and serotonin transporters. J Exp Biol 1994;196:263-81.
47. Bauman AL, Apparsundaram S, Ramamoorthy S, et al. Cocaine and antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A. J Neurosci 2000;20:7571-8.
48. Malmgren R, Åberg-Wistedt A, Bertilsson L. Serotonin uptake inhibition during treatment of depression with nortriptyline caused by parent drug and not by 10-hydroxymetabolites. Psychopharmacology (Berlin) 1987;92:169-72.
49. Green AR. The mechanism of action of antidepressant treatments: basic aspects. Pharmacopsychiatry 1988;21:3-5.
50. de Montigny C, Chaput Y, Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. J Clin Psychiatry 1990;51(Suppl 5):4-8.